Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPT003
MIFTS: 61

Hepatitis a

Categories: Infectious diseases, Liver diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases, Immune diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hepatitis a

About this section

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 12 76 43 44 15 73
Viral Hepatitis, Type a 12
Viral Hepatitis a 12

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases
Anatomical: Liver diseases Gastrointestinal diseases Immune diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:12549
MeSH 44 D006506
NCIt 50 C3096
SNOMED-CT 68 154347003 40468003
ICD10 33 B15.0 B15.9
UMLS 73 C0019159
Sources

Summaries for Hepatitis a

About this section
MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis A, is caused by the hepatitis A virus (HAV). The disease spreads through contact with an infected person's stool. You can get it from Eating food made by an infected person who did not wash their hands after using the bathroom Drinking untreated water or eating food washed in untreated water Putting into your mouth a finger or object that came into contact with an infected person's stool Having close contact with an infected person, such as through sex or caring for someone who is ill Most people do not have any symptoms. If you do have symptoms, you may feel as if you have the flu. You may also have yellowish eyes and skin, called jaundice. A blood test will show if you have HAV. HAV usually gets better in a few weeks without treatment. However, some people can have symptoms for up to 6 months. Your doctor may suggest medicines to help relieve your symptoms. The hepatitis A vaccine can prevent HAV. Good hygiene can also help. Wash your hands thoroughly before preparing food, after using the toilet, or after changing a diaper. International travelers should be careful about drinking tap water. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis a, also known as viral hepatitis, type a, is related to hepatitis and acute liver failure, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and NF-kappaB Signaling. The drugs Aluminum hydroxide and Aluminum sulfate have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and testes.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 76 Hepatitis A is an infectious disease of the liver caused by the hepatitis A virus (HAV). Many cases have... more...

Sources

Related Diseases for Hepatitis a

About this section

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.0 AFP F2 GPT HAVCR1 HAVCR2 IFNA2
2 acute liver failure 30.3 ALB F2 GPT
3 autoimmune hepatitis 30.3 CD40LG F2 GPT
4 typhoid fever 30.2 ALB F2 TNF
5 alcoholic hepatitis 30.2 ALB F2 GPT TNF
6 cholecystitis 30.1 ALB F2 GPT
7 hepatic coma 29.7 ALB F2 GPT
8 livedoid vasculopathy 29.4 CD40LG F2
9 celiac disease 1 29.4 ALB CD40LG TNF
10 sclerosing cholangitis 29.4 ALB CD40LG TNF
11 leptospirosis 29.2 CD40LG F2 TNF
12 meningitis 29.1 ALB CD40LG TNF
13 primary biliary cirrhosis 29.1 ALB CD40LG F2
14 diarrhea 29.0 ALB CD40LG TNF
15 tuberculous peritonitis 29.0 ALB TNF
16 hepatitis e 28.9 ALB CD40LG F2 GPT TNF
17 hepatitis b 28.8 AFP ALB F2 GPT IFNA2 TNF
18 thrombophilia due to thrombin defect 28.7 F2 F3 SERPINC1
19 liver disease 28.6 AFP ALB F2 F3 GPT SERPINA1
20 thrombosis 28.6 F2 F3 SERPINC1
21 scrub typhus 28.4 CD40LG F3 GPT TNF
22 hepatitis d 28.4 CD40LG F2 GPT IFNA2
23 cholangitis 28.2 ALB CD40LG F2 GPT TNF
24 malaria 28.2 ALB CD40LG F3 HAVCR2 TNF
25 purpura 27.9 CD40LG F2 F3 SERPINC1 TNF
26 vasculitis 27.8 CD40LG IFNA2 SERPINA1 TNF
27 dengue hemorrhagic fever 27.7 ALB CD40LG F2 F3 TNF
28 viral hepatitis 26.9 AFP ALB CD40LG F2 GPT IFNA2
29 liver cirrhosis 26.9 AFP ALB F2 GPT SERPINA1 SERPINC1
30 hemorrhagic fever 26.3 ALB CD40LG F2 F3 GPT SERPINC1
31 gianotti crosti syndrome 10.8
32 hepatoid adenocarcinoma 10.8 AFP ALB
33 antipyrine metabolism 10.7 ALB F2
34 non-a-e hepatitis 10.7 ALB F2
35 opisthorchiasis 10.7 AFP GPT
36 adult dermatomyositis 10.7 GPT TNF
37 hepatoportal sclerosis 10.7 F2 GPT
38 abdominal tuberculosis 10.7 ALB F2
39 fatty liver disease 10.7
40 marburg hemorrhagic fever 10.6 F2 TNF
41 endometrial small cell carcinoma 10.6 AFP F2
42 vitamin k deficiency hemorrhagic disease 10.6 AFP F2
43 colorado tick fever 10.6 ALB CD40LG
44 cork-handlers' disease 10.6 ALB CD40LG
45 plasmodium malariae malaria 10.6 ALB CD40LG
46 hemangioma of liver 10.6 F2 IFNA2
47 trench fever 10.5 CD40LG TNF
48 encephalitozoonosis 10.5 CD40LG TNF
49 protein-energy malnutrition 10.5 ALB GPT TNF
50 rheumatoid lung disease 10.5 CD40LG TNF

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a
Sources

Symptoms & Phenotypes for Hepatitis a

About this section

Symptoms:

12
  • • fever
  • • fatigue
  • • loss of appetite
  • • nausea
  • • vomiting
  • • abdominal pain
  • • clay-colored bowel movements
  • • joint pain
  • • jaundice

UMLS symptoms related to Hepatitis a:


abdominal pain, constipation, diarrhea, dyspepsia, fever, heartburn, icterus, nausea and vomiting, pruritus, gastrointestinal gas
Sources

Drugs & Therapeutics for Hepatitis a

About this section

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 816)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
2
Aluminum sulfate Approved Phase 4,Phase 3,Phase 1,Phase 2 10043-01-3
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
5
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
6
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
7
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
8
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
9
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
10
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
11
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 54-85-3 3767
12
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
13
Rifampicin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
14
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
15
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
16
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
17
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
18
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
19
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
20
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
21
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
22
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
23
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
24
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
25
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
26
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
27
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 83-43-2 6741
28
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-24-8 5755
29
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
30
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
31
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
32
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
33
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
34
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
35
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 8008-53-5
36
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6493-05-6 4740
37
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 9552079 2713
38
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 128-13-2 31401
39
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
40
Insulin Glargine Approved Phase 4 160337-95-1
41
Insulin glulisine Approved Phase 4 207748-29-6
42
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 23994
43
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
44
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
45
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 1
46
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 923604-59-5 66576988
47
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 53-03-2 5865
48
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 174722-31-7 10201696
49
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
50
Simethicone Approved Phase 4,Phase 3 8050-81-5

Interventional clinical trials:

(show top 50) (show all 4395)
# Name Status NCT ID Phase Drugs
1 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
2 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
3 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
4 Phase â…£ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®ï¼‰ Unknown status NCT02189603 Phase 4
5 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
6 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
7 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
8 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
9 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
10 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
11 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
12 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
13 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
14 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
15 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
16 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
17 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
18 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
19 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
20 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
21 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
22 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
23 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
24 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
25 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
26 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
27 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
28 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
29 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
30 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
31 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
32 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
33 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
34 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
35 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
36 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
37 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
38 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
39 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
40 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
41 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
42 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
43 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
44 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
45 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
46 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
47 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
48 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
49 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
50 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Sources

Genetic Tests for Hepatitis a

About this section
Sources

Anatomical Context for Hepatitis a

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis a:

19
Liver

MalaCards organs/tissues related to Hepatitis a:

41
Liver, Testes, Kidney, Bone, T Cells, B Cells, Bone Marrow
Sources

Publications for Hepatitis a

About this section

Articles related to Hepatitis a:

(show top 50) (show all 998)
# Title Authors Year
1
Outbreak of Hepatitis A Virus Infection Among Adult Patients of a Mental Hospital-Los Angeles County, 2017 - CORRECTION. ( 29970205 )
2018
2
Complement factor 3 among children with hepatitis A: Assessment of bilirubin levels. ( 29371712 )
2018
3
Minocycline-associated polyarteritis nodosa and self-limiting hepatitis: a reminder of a potentially re-emerging culprit in drug-induced autoimmune syndromes. ( 29532736 )
2018
4
Metagenomic analysis reveals Hepatitis A virus in suspected yellow fever cases in Brazil. ( 29211109 )
2018
5
Travel-associated hepatitis A in Europe, 2009 to 2015. ( 29871720 )
2018
6
Hepatitis A, cardiomyopathy, aplastic anemia, and acute liver failure: A devastating scenario. ( 29359844 )
2018
7
Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: How long persist antibodies to non-structural HAV proteins? ( 29907320 )
2018
8
Duck hepatitis A virus structural proteins expressed in insect cells self-assemble into virus-like particles with strong immunogenicity in ducklings. ( 29426402 )
2018
9
Comparative liver transcriptome analysis in ducklings infected with duck hepatitis A virus 3 (DHAV-3) at 12 and 48A hours post-infection through RNA-seq. ( 29925406 )
2018
10
Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis: A Single-Center Cross-Sectional Study With Pair-Matched Healthy Controls. ( 29847395 )
2018
11
Natural History, Clinical Manifestations, and Pathogenesis of Hepatitis A. ( 29440324 )
2018
12
Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis. ( 29904396 )
2018
13
Hepatitis A vaccination coverage among adolescents (13-17a8^years) in the United States, 2008-2016. ( 29449100 )
2018
14
The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004-2016. ( 29398275 )
2018
15
Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection. ( 29427580 )
2018
16
A Case of Graves' Disease Accompanied with Acute Hepatitis A Virus Infection. ( 29943563 )
2018
17
Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis- A Multinational, Prospective, Controlled, Randomized Trial. ( 29385313 )
2018
18
Pathogenicity of duck hepatitis A virus type 3 and innate immune responses of the ducklings to virulent DHAV-3. ( 29407574 )
2018
19
Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )
2018
20
Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis C. ( 29846860 )
2018
21
Immunization Against Hepatitis A Virus and Hepatitis B Virus in Patients with Chronic Liver Disease: Are We Doing a Good Job? ( 29942730 )
2018
22
Evidence of hepatitis A virus infection in the patients with acute encephalitis syndrome in Gorakhpur region, North India. ( 29895163 )
2018
23
Lumbar synovial cyst with chronic viral hepatitis: A case series and literature review. ( 29724648 )
2018
24
Experimental infection of Marmota monax with a novel hepatitis A virus. ( 29387970 )
2018
25
Relationship of Severity of Hepatitis A with Polymorphisms in Hepatitis A Virus Cellular Receptor 1 (HAVCR1) Gene. ( 29893695 )
2018
26
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. ( 29380498 )
2018
27
Tumor Necrosis Factor-producing T-regulatory Cells AreA Associated With Severe Liver Injury in Patients With AcuteA Hepatitis A. ( 29229400 )
2018
28
Hepatitis A, B, and A/B vaccination series completion among US adults: a claims-based analysis. ( 29923789 )
2018
29
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
30
Protective efficacy of a bivalent live attenuated vaccine against duck hepatitis A virus types 1 and 3 in ducklings. ( 29408021 )
2018
31
Spillover of a hepatitis A outbreak among men who have sex with men (MSM) to the general population, the Netherlands, 2017. ( 29897040 )
2018
32
Group C Streptococcal Sore Throat with Hepatitis - a Rare Association. ( 29870104 )
2018
33
Response to comment on: Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. ( 29907321 )
2018
34
Improved TaqMan real-time assays for detecting hepatitis A virus. ( 29409997 )
2018
35
Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis. ( 29324766 )
2018
36
Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study. ( 29885414 )
2018
37
HAVCR1 (CD365) and its mouse ortholog are functional hepatitis A virus (HAV) cellular receptors that mediate HAV infection. ( 29437974 )
2018
38
Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage. ( 29381561 )
2018
39
Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France. ( 29886426 )
2018
40
Leucopenia: A Rare Extrahepatic Manifestation of Acute Hepatitis A. ( 29892189 )
2018
41
Decrease in seroprevalence of hepatitis A virus in Santiago, Chile: A decade-long comparison. ( 29871761 )
2018
42
Causal relationship between acute pancreatitis and methylprednisolone pulse therapy for fulminant autoimmune hepatitis: a case report and review of literature. ( 29881634 )
2018
43
Steroid therapy in children with fulminant hepatitis A. ( 29397017 )
2018
44
Acute Exacerbation to Autoimmune Hepatitis Mimicking Acute Viral Hepatitis-A Case Series and Review of Literature. ( 29743801 )
2018
45
Seropositivity of Hepatitis A in Children Aged 7-14 Years in Diyarbakir Province Center. ( 29445079 )
2018
46
Molecular genetic identification of isolates of the hepatitis A virus (HAV) from monkeys at Adler Primate Center. ( 29380396 )
2018
47
A Randomized Controlled Trial to Evaluate a Potential Hepatitis B Booster Vaccination Strategy Using Combined Hepatitis A and B Vaccine. ( 28060048 )
2017
48
A large prolonged outbreak of hepatitis A associated with consumption of frozen berries, Italy, 2013-14. ( 28086079 )
2017
49
TIM1 (HAVCR1) Is Not Essential for Cellular Entry of Either Quasi-enveloped or Naked Hepatitis A Virions. ( 28874468 )
2017
50
Hepatitis A with Superadded Salmonella paratyphi A Infection Presenting with Exudative Pleural Effusion and Acalculous Cholecystitis. ( 28667735 )
2017
Sources

Variations for Hepatitis a

About this section
Sources

Expression for Hepatitis a

About this section
Search GEO for disease gene expression data for Hepatitis a.
Sources

Pathways for Hepatitis a

About this section

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 12.58 ALB F2 F3 HSPA5 IFNA2 SERPINA1
2
NF-kappaB Signaling 4
12.14 CD40LG HAVCR1 HAVCR2 TNF
3
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.78 F2 F3 SERPINC1
4
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.67 AFP ALB SERPINA1
5
T Cell Co-Signaling Pathway: Ligand-Receptor Interactions 65
11.2 CD40LG HAVCR1 HAVCR2
6
Complement and coagulation cascades 1 37
11.07 F2 F3 SERPINA1 SERPINC1
7
FOXA2 and FOXA3 transcription factor networks 1
10.98 AFP ALB F2
Sources

GO Terms for Hepatitis a

About this section

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.92 ALB F2 F3 GPT HAVCR2 HSPA5
2 extracellular region GO:0005576 9.81 AFP ALB CD40LG F2 F3 IFNA2
3 cell surface GO:0009986 9.65 CD40LG F3 HAVCR2 HSPA5 TNF
4 endoplasmic reticulum lumen GO:0005788 9.43 AFP ALB F2 HSPA5 SERPINA1 SERPINC1
5 extracellular space GO:0005615 9.32 AFP ALB CD40LG F2 F3 GPT

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.78 CD40LG F2 IFNA2 TNF
2 inflammatory response GO:0006954 9.71 CD40LG HAVCR2 IFNA2 TNF
3 post-translational protein modification GO:0043687 9.67 AFP ALB SERPINA1 SERPINC1
4 cellular protein metabolic process GO:0044267 9.55 AFP ALB F2 SERPINA1 SERPINC1
5 negative regulation of interleukin-6 production GO:0032715 9.49 HAVCR2 TNF
6 positive regulation of interleukin-4 production GO:0032753 9.46 CD40LG HAVCR2
7 positive regulation of chemokine production GO:0032722 9.43 HAVCR2 TNF
8 blood coagulation GO:0007596 9.35 F2 F3 IFNA2 SERPINA1 SERPINC1
9 regulation of blood coagulation GO:0030193 9.32 F2 SERPINC1
10 regulation of immunoglobulin secretion GO:0051023 9.26 CD40LG TNF
11 hemostasis GO:0007599 8.92 F2 F3 SERPINA1 SERPINC1

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.92 F3 SERPINA1 SERPINC1 TNF
Sources

Sources for Hepatitis a

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....